Navigation Links
New technique uses 'simulated' human heart to screen drugs
Date:7/21/2014

A Coventry University scientist has developed a pioneering new way using samples of beating heart tissue to test the effect of drugs on the heart without using human or animal trials.

The breakthrough is the work of Dr Helen Maddock an expert in cardiovascular physiology and pharmacology from the University's Centre for Applied Biological and Exercise Sciences and could lead to the lives of hundreds of future patients being saved and the quality of their treatments improved.

Adverse effects of drugs on the cardiovascular system are a major cause of many medical treatments failing, but heart-related side-effects can often only be detected once a drug is being used on patients in clinical trials by which time it is too late.

Dr Maddock's 'in vitro' technique which means 'in glass' in reference to it taking place in a laboratory environment rather than in a living organism uses a specimen of human heart tissue attached to a rig allowing the muscle to be lengthened and shortened whilst being stimulated by an electrical impulse, mimicking the biomechanical performance of cardiac muscle.

Trial drugs can then be added to the tissue to determine whether or not they have an adverse effect on the force of contraction of the muscle (and therefore of the heart), a test that could only previously be performed 'in vivo' i.e. on living animals often with inconclusive results.

This 'simulated' cardiovascular system known as a work-loop assay provides the most realistic model of heart muscle dynamics in the world to date, and opens up unprecedented possibilities for identifying negative effects of drugs early and inexpensively potentially saving lives and speeding up the development of successful drug treatments.

Dr Maddock has formed a spin-out company InoCardia Ltd from Coventry University to begin implementing her groundbreaking technique in the pharma industry, and it has already received a quarter of a million pound investment from Warwickshire-based technology investment firm Mercia Fund Management.

Dr Maddock, who spent almost ten years developing the technique, said:

"I'm delighted that our research is at a stage where we can confidently say the work-loop assay we've created is the world's only clinically relevant in vitro human model of cardiac contractility. It has the potential to shave years off the development of successful drugs for a range of treatments.

"Both the pharma industry and regulators recognise that existing methods of assessing the contractility of the heart are fraught with problems, so we're incredibly excited to be able to introduce a new way to accurately determine the safety of drugs in respect of the heart without the need to test on humans or animals."

Mark Payton, managing director of Mercia Fund Management, added:

"InoCardia benefits from a proprietary approach following many years of investigation by Helen and her team, and offers the potential for early screening of compounds in development without the initial need for extensive animal trials. Through a markedly accelerated drug development process, this will decrease timelines to drug development, and as a consequence greatly reduce the cost of new drug development. The end beneficiary will, of course, be patients receiving novel treatments sooner."

Dr Maddock and InoCardia Ltd are already in discussions with a multinational biopharmaceutical company with a view to applying the assay in industry.


'/>"/>

Contact: Alex Roache
alex.roache@coventry.ac.uk
44-024-776-55050
Coventry University
Source:Eurekalert  

Related biology news :

1. New technique maps lifes effects on our DNA
2. Innovative technique may transform the hunt for new antibiotics and cancer therapies
3. Grass-in-the-ear technique sets new trend in chimp etiquette
4. Research team pursues techniques to improve elusive stem cell therapy
5. Big data technique improves monitoring of kidney transplant patients
6. New digital fabrication technique creates interlocking 3D-printed ceramic PolyBricks
7. Criminal profiling technique targets killer diseases
8. Developing an improved liposuction technique that melts fat
9. New technique to prevent anal sphincter lesions due to episiotomy during child delivery
10. Novel ORNL technique enables air-stable water droplet networks
11. Study validates air sampling techniques to fight bioterrorism
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New technique uses 'simulated' human heart to screen drugs
(Date:1/19/2017)... , January 19, 2017 According to a new ... and Forecast, 2014 - 2022," the global biometric sensor market is expected to ... to 2022. In 2015, Asia-Pacific dominated the global market ... private sectors. Continue Reading ... ...
(Date:1/18/2017)... 2017  In vitro diagnostic (IVD) companies were very ... (M&A), and Kalorama Information expects that trend to continue ... shifting. Generally, uncertainty in reimbursement and healthcare reform in ... changed the acquisitions landscape. Instead of looking to buy ... partners outside of their home country and also to ...
(Date:1/13/2017)... PORT WASHINGTON, N.Y. , Jan. 13, 2017 ... provider of technology solutions for the homecare industry, ... appointment of homecare industry expert, Justin Jugs, as ... Justin brings more than 15 years of homecare ... the team in developing strategic plans to align ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies ... Marbán, Ph.D, president and chief executive officer, is scheduled to ... Cowen and Company 37th Annual Health Care Conference Tuesday, March ... 29th Annual ROTH Conference Tuesday, ... Dana Point, CA ...
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017 ... company, and Beyond Type 1, a not-for-profit advocacy and ... today announced a grant from Beyond Type 1 to ... type 1 and other insulin-requiring diabetes.  ... innovative stem cell-derived cell replacement therapies with a focus ...
(Date:2/22/2017)... Kan. , Feb. 22, 2017  Aratana Therapeutics, Inc. ... development and commercialization of innovative biopharmaceutical products for companion animals, ... 2017 at 8:30 a.m. ET to discuss financial results from ... Interested participants and investors may access the ... ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , a leader in ... for all SPIE attendees and Park customers on Feb. 27, 2017 from ... San Jose Convention Center. The luncheon will feature a talk on Automated AFM ...
Breaking Biology Technology: